Direct comparison
Illumina vs Nanopore: Procurement Guide
Compare Illumina short-read and Oxford Nanopore long-read sequencing on accuracy, cost, throughput, and data burden to guide a lab purchase decision.
Ask about Illumina vs Nanopore: Procurement Guide
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do Illumina (SBS), Oxford Nanopore compare side by side?
The table below compares Illumina (SBS), Oxford Nanopore across 13 procurement-relevant dimensions, from core method through regulatory/clinical use.
Side-by-side comparison
| Dimension | Illumina (SBS) | Oxford Nanopore |
|---|---|---|
| Core method | Sequencing-by-synthesis: clonal amplification + cyclic reversible-terminator chemistry, imaged optically | Single-molecule nanopore sensing: native strand translocation through a protein pore, basecalled from ionic-current signal |
| Read length | Short reads, typically ~50-300 bp per read depending on kit | Long reads set by native fragment length -- kilobases and up |
| Amplification required | Yes (clonal amplification on the flow cell) | No -- can sequence native, unamplified DNA/RNA |
| Base modification detection (e.g. methylation) | Requires separate conversion step (e.g. bisulfite) | Detectable directly from native signal in many workflows |
| Single-read accuracy | Very high per-base accuracy, historically the platform benchmark | Improved substantially across chemistry generations; verify current kit-specific figures with the vendor |
| Real-time / adaptive run control | No -- results available after the run completes | Yes -- streaming basecalling, early stop, and adaptive (selective) sampling |
| Entry-level capital cost | Benchtop tier (e.g. iSeq/MiniSeq/MiSeq-class) is the lowest Illumina entry point | MinION/Flongle entry point is typically lower capital cost than comparable Illumina tiers |
| Production-scale tier | NovaSeq-class systems for population-scale throughput | PromethION for production-scale throughput |
| Consumables cost model | Per-run flow cell cost, economics improve with multiplexed batch size | Per-flow-cell cost, can be run individually or in parallel; some reuse possible within a defined lifespan |
| Typical turnaround | Hours to over a day depending on flow cell output tier; results after run completion | First results within minutes of run start; run can be stopped once sufficient depth is reached |
| Best-fit applications | Variant calling, targeted panels, RNA-seq quantification, validated clinical short-read pipelines | De novo assembly, structural variants, full-length transcripts, metagenomic strain resolution, field/portable use |
| Bioinformatics ecosystem | Largest existing base of validated short-read pipelines and reference workflows | Requires long-read-aware aligners/callers; signal data can be larger per sample |
| Regulatory/clinical use | Some kits/workflows carry FDA clearance for specific clinical uses; confirm per assay | Some kits/workflows carry FDA clearance for specific clinical uses; confirm per assay |
Common questions
Common questions about Illumina (SBS) vs Oxford Nanopore
How does nanopore sequencing work?
+
A single strand of native DNA or RNA passes through a protein nanopore embedded in a membrane; an applied voltage drives translocation, and each base passing through the pore's narrowest point disrupts the ionic current in a base-dependent way. That signal is recorded continuously and converted into a base sequence in real time by a machine-learning basecaller, without amplification or synthesis.
Is Illumina or Nanopore more accurate?
+
They aren't directly comparable on one number. Illumina's short-read chemistry has historically delivered higher single-read, per-base accuracy; Nanopore's raw accuracy has improved substantially across chemistry generations and can approach short-read accuracy at sufficient consensus depth, while providing read lengths and native-molecule information Illumina cannot. Request current, kit-specific figures from both vendors for your exact use case.
Which platform costs less to procure and operate?
+
Nanopore's entry-level instruments have a materially lower capital entry point. Total cost of ownership at real sample volume depends on multiplexing plan, sample type, and service contract terms on both sides -- request a fully-loaded quote at your projected annual volume from each vendor.
Can a lab use both platforms together?
+
Yes. Hybrid sequencing strategies combining Nanopore long reads with Illumina short reads (commonly for assembly polishing) are an established approach, and many core facilities run or access both because the platforms are complementary for different project types.
What accreditation considerations apply when procuring a sequencing platform for regulated work?
+
Confirm FDA clearance status for the specific kit/workflow you intend to use, and confirm with your accrediting body (e.g. under CLIA and/or ISO 15189) what instrument configuration, reagent lot control, software versioning, and audit-trail practices are required to keep the assay within accredited scope.
